SI2828242T1 - Nove polimorfne kristalinične oblike 5-(2-((6-(2,2-difluoro-2-feniletoksi)heksil)amino)-1-(r)-hidroksietil) -8-hidroksikinolin-2(1h)-on, heminapadisilata kot agonista adrenergič- nega receptorja beta2 - Google Patents

Nove polimorfne kristalinične oblike 5-(2-((6-(2,2-difluoro-2-feniletoksi)heksil)amino)-1-(r)-hidroksietil) -8-hidroksikinolin-2(1h)-on, heminapadisilata kot agonista adrenergič- nega receptorja beta2

Info

Publication number
SI2828242T1
SI2828242T1 SI201330823T SI201330823T SI2828242T1 SI 2828242 T1 SI2828242 T1 SI 2828242T1 SI 201330823 T SI201330823 T SI 201330823T SI 201330823 T SI201330823 T SI 201330823T SI 2828242 T1 SI2828242 T1 SI 2828242T1
Authority
SI
Slovenia
Prior art keywords
heminapadisylate
hydroxyquinolin
phenylethoxy
difluoro
agonist
Prior art date
Application number
SI201330823T
Other languages
English (en)
Inventor
Mestres Gemma Amat
Ardanuy Elvira Balaguer
Carrera Francesc Carrera
Hereu Iolanda Marchueta
Valls Enrique Moyes
Original Assignee
Almirall S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45894403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2828242(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall S.A. filed Critical Almirall S.A.
Publication of SI2828242T1 publication Critical patent/SI2828242T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
SI201330823T 2012-03-20 2013-03-15 Nove polimorfne kristalinične oblike 5-(2-((6-(2,2-difluoro-2-feniletoksi)heksil)amino)-1-(r)-hidroksietil) -8-hidroksikinolin-2(1h)-on, heminapadisilata kot agonista adrenergič- nega receptorja beta2 SI2828242T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12382101.9A EP2641900A1 (en) 2012-03-20 2012-03-20 Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
US201261622266P 2012-04-10 2012-04-10
EP13719407.2A EP2828242B1 (en) 2012-03-20 2013-03-15 NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR.
PCT/EP2013/055488 WO2013139712A1 (en) 2012-03-20 2013-03-15 NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR.

Publications (1)

Publication Number Publication Date
SI2828242T1 true SI2828242T1 (sl) 2017-12-29

Family

ID=45894403

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330823T SI2828242T1 (sl) 2012-03-20 2013-03-15 Nove polimorfne kristalinične oblike 5-(2-((6-(2,2-difluoro-2-feniletoksi)heksil)amino)-1-(r)-hidroksietil) -8-hidroksikinolin-2(1h)-on, heminapadisilata kot agonista adrenergič- nega receptorja beta2

Country Status (29)

Country Link
US (1) US9346759B2 (sl)
EP (2) EP2641900A1 (sl)
JP (1) JP6134377B2 (sl)
KR (1) KR101856818B1 (sl)
CN (1) CN104203918B (sl)
AR (1) AR090448A1 (sl)
AU (1) AU2013234514B2 (sl)
CA (1) CA2862934C (sl)
CL (1) CL2014002440A1 (sl)
CO (1) CO7081154A2 (sl)
CR (1) CR20140433A (sl)
EA (1) EA030015B1 (sl)
ES (1) ES2646776T3 (sl)
HK (1) HK1201832A1 (sl)
HR (1) HRP20171982T1 (sl)
HU (1) HUE037364T2 (sl)
IL (1) IL234175B (sl)
MX (1) MX351293B (sl)
MY (1) MY172680A (sl)
NZ (1) NZ628697A (sl)
PE (1) PE20142336A1 (sl)
PH (1) PH12014502097A1 (sl)
PL (1) PL2828242T3 (sl)
RS (1) RS56794B1 (sl)
SG (2) SG10201607630WA (sl)
SI (1) SI2828242T1 (sl)
UY (1) UY34699A (sl)
WO (1) WO2013139712A1 (sl)
ZA (1) ZA201405480B (sl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
CR20180594A (es) 2016-06-02 2019-07-29 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
ES2928785T3 (es) 2017-10-13 2022-11-22 Treeway Tw001 B V Sal de edaravona
RU2020117698A (ru) 2017-12-01 2022-01-04 Эббви Инк. Агонист глюкокортикоидного рецептора и его иммуноконъюгаты
CN111748010B (zh) * 2019-03-29 2023-12-08 天津药业研究院股份有限公司 一种醋丙甲泼尼龙无水晶型及其组合物

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT334335B (de) 1973-03-01 1976-01-10 Basf Ag Verfahren zur herstellung von 1-phenyl-2-aminoathanolen-(1)
US2579479A (en) 1950-01-23 1951-12-25 Syntex Sa delta 1, 4-pregnadiene-17alpha-ol-3-ones
US2837464A (en) 1955-01-11 1958-06-03 Schering Corp Process for production of dienes by corynebacteria
US2897216A (en) 1954-11-01 1959-07-28 Schering Corp Process for the preparation of steroidal dienes and intermediates obtained thereby
DE1113690B (de) 1957-02-27 1961-09-14 Merck & Co Inc Verfahren zur Herstellung von in 11-Stellung durch sauerstoffhaltige Gruppen substituierten 16-Methyl-1, 4-pregnadien-17ª‡-ol-3, 20-dion-Verbindungen
US3053865A (en) 1958-03-19 1962-09-11 Merck & Co Inc Novel 16-alkyl and 16-alkylene steroids and processes
GB869511A (en) 1958-05-26 1961-05-31 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
US3007923A (en) 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
US3104246A (en) 1961-08-18 1963-09-17 Roussel Uclaf Process of preparation of beta-methasone
US3134718A (en) 1963-12-12 1964-05-26 Schering Corp Pregna-1,4-dienes and compositions containing same
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
GB1247370A (en) 1968-12-31 1971-09-22 Allen & Hanburys Ltd Glyoxals and production thereof
US3678137A (en) 1970-10-15 1972-07-18 Smith Kline French Lab Adamantyl-substituted-alkyl 2-aminoethyl phosphates and phosphonates
BE786713A (fr) 1971-07-27 1973-01-25 Sandoz Sa Nouveaux amino-alcools, leur preparation et leur application comme medicaments
SE378109B (sl) 1972-05-19 1975-08-18 Bofors Ab
US4068076A (en) 1972-12-29 1978-01-10 Otsuka Pharmaceutical Co., Ltd. 5-(1-Hydroxy-2-(heterocyclic amino))ethyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
US3975391A (en) 1973-12-26 1976-08-17 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
DE2310140A1 (de) 1973-03-01 1974-09-12 Basf Ag Neue 1-phenyl-2-amino-aethanolderivate und ein verfahren zu ihrer herstellung
GB1468156A (en) 1973-07-19 1977-03-23 Ici Ltd Phenylethylamine derivatives
US4022776A (en) 1974-01-31 1977-05-10 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxycarbostyril derivatives
JPS5649907B2 (sl) 1974-02-01 1981-11-25
US4022784A (en) 1974-01-31 1977-05-10 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-substituted-carbostyril and -3,4-dihydrocarbostyril derivatives
US3994901A (en) 1974-06-13 1976-11-30 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
US4145542A (en) 1974-06-13 1979-03-20 Otsuka Pharmaceutical Co., Ltd. 5- 1-Hydroxy-2-(heterocyclic-amino)!alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
JPS597706B2 (ja) 1975-06-13 1984-02-20 オオツカセイヤク カブシキガイシヤ カルボスチリルユウドウタイノセイゾウホウ
DE2965655D1 (en) 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
IT7920688V0 (it) 1979-02-05 1979-02-05 Chiesi Paolo Parma Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
US4254130A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
DE3260474D1 (en) 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
JPS6010032B2 (ja) 1983-10-31 1985-03-14 大塚製薬株式会社 カルボスチリル誘導体
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
PH24383A (en) 1984-06-11 1990-06-13 Glaxo Group Ltd Ethanolamine
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
US4937268A (en) 1987-03-12 1990-06-26 Glaxo Group Limited Chemical compounds
ES2039646T3 (es) 1987-11-13 1993-10-01 Glaxo Group Limited Derivados de fenetanolamina.
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
JPH03178929A (ja) 1989-09-07 1991-08-02 Glaxo Group Ltd 炎症及びアレルギー治療用化合物
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
US5507281A (en) 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
EP0640354B1 (en) 1990-09-26 2001-12-05 Pharmachemie B.V. Whirl chamber powder inhaler
US5648370A (en) 1990-11-20 1997-07-15 Astra Pharmaceuticals Limited 7-(2-aminoethyl) benzothiazolones
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
MY115140A (en) 1992-12-18 2003-04-30 Schering Corp Inhaler for powdered medications
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
BR9604977A (pt) 1995-04-14 1998-06-09 Glaxo Wellcome Inc Inalador de dose medida sistema inalador de dose medida e uso do mesmo
NZ306319A (en) 1995-05-08 1999-08-30 Hoechst Marion Roussel Inc 1-alkylphenyl substituted 4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butanol derivatives and medicaments
HU220227B (hu) 1995-06-21 2001-11-28 Asta Medica A.G. Gyógyszerporos patron integrált adagolószerkezettel és inhalálókészülék poralakú gyógyszerekhez
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
ATE215369T1 (de) 1996-09-05 2002-04-15 Lilly Co Eli Carbazolanaloge als selektive beta3-adrenergische agonisten
WO1998009632A1 (en) 1996-09-06 1998-03-12 Merck & Co., Inc. Methods and compositions for treating preterm labor
SE9704644D0 (sv) 1997-12-12 1997-12-12 Astra Ab New use
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
EP1862164A3 (de) 1998-11-13 2012-12-26 Jagotec AG Trockenpulver zur Inhalation
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
AUPQ407699A0 (en) 1999-11-16 1999-12-09 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
EP1305329B2 (en) 2000-08-05 2015-03-18 Glaxo Group Limited 6.alpha.,9.alpha.-difluoro-17.alpha.-(2-furanylcarboxyl)oxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE365720T1 (de) 2001-03-08 2007-07-15 Glaxo Group Ltd Agonisten von beta-adrenorezeptoren
WO2002092606A1 (fr) 2001-05-15 2002-11-21 Takeda Chemical Industries, Ltd. Derives d'imidazolidine fusionnes, leur procede de preparation et d'utilisation
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
EP1497261B1 (en) 2002-04-25 2007-12-19 Glaxo Group Limited Phenethanolamine derivatives
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US6747043B2 (en) 2002-05-28 2004-06-08 Theravance, Inc. Alkoxy aryl β2 adrenergic receptor agonists
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
TW200409746A (en) 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
TW200510277A (en) 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
US20050148563A1 (en) 2003-09-26 2005-07-07 Schering Corporation Pulmonary disease treatment
GB0324654D0 (en) 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324897D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
PE20050973A1 (es) 2003-10-29 2005-11-19 Theravance Inc Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
EP1577291A1 (en) 2004-03-17 2005-09-21 Pfizer Limited Phenylethanolamine derivatives as beta-2 agonists
EP1730103B1 (en) 2004-03-23 2010-05-26 Pfizer Limited Formamide derivatives useful as adrenoceptor
JP4550884B2 (ja) 2004-04-09 2010-09-22 ハンミ ファーム． シーオー．， エルティーディー． 結晶性クロピドグレルナフタレンスルホン酸塩又はその水和物、その製造方法及びそれを含む医薬組成物
WO2005121065A2 (en) 2004-06-03 2005-12-22 Theravance, Inc. DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
SI1616592T1 (sl) 2004-07-16 2011-03-31 Almirall Sa Inhalator za uporabo farmacevtskih snovi v prahu in vloĹľek za prah za uporabo s tem inhalatorjem
US7317023B2 (en) 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
GB0425057D0 (en) 2004-11-12 2004-12-15 Pfizer Ltd L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide
US20060205949A1 (en) 2005-03-10 2006-09-14 Theravance, Inc. Crystalline forms of a biphenyl compound
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
ES2296516B1 (es) 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2570934T3 (es) 2006-06-12 2016-05-23 Novartis Ag Sales de N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)etil]amino]metil]fenil]-2E-2-propenamida
ES2302447B1 (es) 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
EP1953143A1 (en) 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2364727T3 (es) 2007-03-16 2011-09-13 Pfizer Limited Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2,2-difenilhexanamida.
EP1988079A1 (en) 2007-04-25 2008-11-05 Lonza Ag Process for the preparation of optically active ethenylphenyl-alcohols
JP2010536872A (ja) 2007-08-22 2010-12-02 アラーガン、インコーポレイテッド 治療用キノリンおよびナフタレン誘導体
WO2009026584A1 (en) 2007-08-23 2009-02-26 Novelmed Therapeutics, Inc. Methods of treating inflammatory conditions with adrenergic antagonists
US8501994B2 (en) 2007-08-28 2013-08-06 Sunovion Pharmaceuticals Inc. Acetamide stereoisomer
US20110105449A1 (en) 2007-11-07 2011-05-05 Astrazeneca R&D Dry powder formulations comprising ascorbic acid derivates
ES2320961B1 (es) 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2221297A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
EP2221055A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
EP2228368A1 (en) * 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2647627A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
EP2668941A1 (en) 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol

Also Published As

Publication number Publication date
CA2862934A1 (en) 2013-09-26
MX2014010798A (es) 2015-01-14
PE20142336A1 (es) 2015-01-09
MX351293B (es) 2017-10-10
KR101856818B1 (ko) 2018-05-10
EA201401027A1 (ru) 2015-03-31
EP2641900A1 (en) 2013-09-25
CL2014002440A1 (es) 2014-11-03
WO2013139712A1 (en) 2013-09-26
PH12014502097B1 (en) 2014-11-24
KR20140135770A (ko) 2014-11-26
ZA201405480B (en) 2015-05-27
JP2015510907A (ja) 2015-04-13
CA2862934C (en) 2019-03-12
HRP20171982T1 (hr) 2018-02-23
MY172680A (en) 2019-12-10
RS56794B1 (sr) 2018-04-30
AU2013234514A1 (en) 2014-09-11
NZ628697A (en) 2016-03-31
AR090448A1 (es) 2014-11-12
HK1201832A1 (en) 2015-09-11
SG11201405590XA (en) 2014-10-30
PL2828242T3 (pl) 2018-01-31
EP2828242A1 (en) 2015-01-28
EP2828242B1 (en) 2017-10-04
IL234175B (en) 2018-10-31
US9346759B2 (en) 2016-05-24
AU2013234514B2 (en) 2017-05-11
UY34699A (es) 2013-10-31
CN104203918B (zh) 2017-01-18
SG10201607630WA (en) 2016-11-29
EA030015B1 (ru) 2018-06-29
CO7081154A2 (es) 2014-10-10
HUE037364T2 (hu) 2018-09-28
CN104203918A (zh) 2014-12-10
PH12014502097A1 (en) 2014-11-24
JP6134377B2 (ja) 2017-05-24
ES2646776T3 (es) 2017-12-15
CR20140433A (es) 2014-11-04
US20150057256A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
SI2367796T1 (sl) Mezilatova sol 5-(2-((6-(2,2-difluoro-2-feniletoksi)heksil)amino)-1- hidroksietil)-8-hidroksikvinolin-2(1h)-ona kot agonist adrenergiäśnega beta2 receptorja
HK1201832A1 (en) Novel polymorphic crystal forms of 5-(2-[6-(2,2-difluoro-2- phenylethoxy)hexyl]amino-1-(r)-hydroxyethyl)-8-hydroxyquinolin- 2(1h)-one, heminapadisylate as agonist of the 2 adrenergic receptor. 2 5-(2-[6-(2,2--2-) ] -1-(r)-)-8--2(1h)-,
DK3686193T3 (da) 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
ATE551323T1 (de) Napadisilatsalz von 5-(2-ää6-(2,2-difluoro-2- phenylethoxy)hexylüaminoü-1-hydroxyethyl)-8- hydroxyquinolin-2(1h)-on als agonist des beta-2- adrenergen rezeptors
HK1199022A1 (zh) -三唑- -基 苯甲酰胺及 -三唑- -基 吡啶酰胺衍生物
EP3376865A4 (en) 4 - ((6- (2,4-difluorophenyl) -1,1-difluoro-2-HYDROXY-3- (1 H
IL220851A (en) Process for the preparation of n - (2 - (2 - (4 - (2 - (7,6-dimethoxy-4,3-dihydro-iso-quinoline-2 - (1 h))) ethyl) phenyl) - h2 - tetrazole - 5-ram (5,4-dimethoxyphenyl) -4-oxo-h4-chromium-2-carboxamide methane-sulfonate, its intermediate and intermediate preparation process
HK1225736B (zh) (s)-(2-(6-氯-7-甲基-1h-苯並[d]咪唑-2-基)-2-甲基吡咯烷-1-基)(5-甲氧基-2-(2h-1，2，3-三唑-2-基)苯基)甲酮作為食欲素受體拮抗劑的結晶鹽形式
SMT201300019B (it) Procedimento per la fabbricazione di 5-(2-{[6-(2,2-difluoro-2-feniletossi)esil]ammino]}-1-idrossietil)-8-idrossichinolin-2(1H)-one
HK1225731B (zh) (s)-(2-(6-氯-7-甲基-1h-苯並[d]咪唑-2-基)-2-甲基吡咯啶-1-基)(5-甲氧基-2-(2h-1，2，3-三唑-2-基)苯基)甲酮的晶形及其作為食欲素受體拮抗劑的用途
IL231284A0 (en) Process for preparing, 5 – (2 – {[6 – (2,2 – difluoro – 2 – phenylethoxy)hexyl] amino} – 1 (r) – hydroxyethyl) – 8 – hydroxyquinoline – 2 (1h) – one by an intermediate compound new